Safety, tolerability, and efficacy of high versus low-dose, short versus long-course daily primaquine for the radical cure of uncomplicated Plasmodium vivax malaria in children under 15 years of age: an open-label, non-inferiority, randomized controlled trial (CHILDPRIM)

Abstract Background Primaquine (PQ) is widely used to prevent Plasmodium vivax relapses. However, the most efficacious and safest dose is unknown, particularly in children. This trial assessed the safety, tolerability, and efficacy of two high-dose PQ regimens compared with standard of care (SoC) in...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ana Luisa O. Pacheco, Aretha G. Omena, Djane C. Baía-da-Silva, Tyane A. P. Jardim, Debora C. B. Silva, Adriana P. B. Lopes, Laila R. A. Barbosa, Ingrid G. Souza, Renata F. Araujo, Luis O. S. Nogueira, Suianne C. N. Vale, Gisely C. Melo, Jady S. M. Cordeiro, Quique Bassat, Vanderson S. Sampaio, Valéria D. S. Lima, Flor E. Martinez-Espinosa, Maria Paula G. Mourão, Wuelton M. Monteiro, Maria Graças C. Alecrim, Jose Diego Brito-Sousa, Marcus V. G. Lacerda
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2025-12-01
Ráidu:	Malaria Journal
Fáttát:	Plasmodium vivax Malaria Children Paediatric Primaquine 8-Aminoquinolines
Liŋkkat:	https://doi.org/10.1186/s12936-025-05686-y
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!